Dacomitinib

Study of Dacomitinib and Osimertinib for Patients With Advanced EGFR Mutant Lung Cancer

Dacomitinib in Lung Cancer With Uncommon EGFR Mutations

Dacomitinib Plus PD-0325901 in Advanced KRAS Mutant NSCLC

Phase 2 Study of Dacomitinib in NSCLC

Real World Utilization and Outcomes With Dacomitinib First Line Treatment for EGFR Mutation-positive Advanced Non Small Cell Lung Cancer Among Asian Patients - A Multi Center Chart Review

A Pilot Study of Dacomitinib With or Without Osimertinib for Patients With Metastatic EGFR Mutant Lung Cancers With Disease Progression on Osimertinib.

A Study to Learn About the Effectiveness of Cancer Medicines in Patients With Metastatic Non-small Cell Lung Cancer in Norway.

Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating Mutations

Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

The Drug Rediscovery Protocol (DRUP Trial)

First-line Treatment With Dacomitinib Plus Anlotinib for Patients With Advanced NSCLC With EGFR 21L858R Mutations

Best EGFR-TKI Sequence in NSCLC Harboring EGFR Mutations

A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)

Dacomitinib (PF-00299804) in Advanced/Metastatic Squamous Cell Carcinoma of the Penis

Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSCLC

Central Nervous System(CNS) Efficacy of Dacomitinib

Evaluate Severe Hepatic Impairment on Dacomitinib PK

Bevacizumab Plus EGFR-TKIs in Chinese Patients With EGFR-mutant NSCLC: a Real-world Study

A Rollover Protocol of Dacomitinib For Patients In Japan

An Open Label, Multicenter, Phase II Study of Dacomitinib for EGFR Mutated Non-Small Cell Lung Cancer (NSCLC) With Brain Metastases